Regeneron Pharmaceuticals Earnings Call Transcripts
Fiscal Year 2026
-
The meeting approved all board proposals, including director elections, auditor ratification, and executive compensation. Strong financial growth was reported, with significant R&D investment and pipeline expansion highlighted. No shareholder questions were submitted.
-
Strong Q1 growth was driven by core franchises, with EYLEA HD and DUPIXENT showing momentum. The pipeline remains robust, with key catalysts expected in the second half, including regulatory and clinical milestones. Strategic flexibility in M&A and collaborations, plus a focus on IP protection and next-generation assets, position the company for long-term growth.
-
Secured relief from government pricing mandates and committed $9B to U.S. R&D and manufacturing through 2030. Dupixent leads in multiple indications, with strong COPD uptake and next-gen candidates in development. EYLEA HD shows robust growth, and oncology pipeline advances with fianlimab and LIBTAYO.
-
Q1 2026 saw 19% revenue growth and 15% EPS growth, driven by strong Dupixent, EYLEA HD, and Libtayo sales. Key pipeline advances, new collaborations, and a $3B share repurchase authorization position the company for continued momentum.
-
The C5 program utilizes a flexible siRNA and antibody approach to tailor complement inhibition for diseases like PNH, gMG, and Geographic Atrophy, showing strong efficacy and safety in late-stage trials. Commercial strategy targets multi-billion-dollar markets with differentiated dosing and administration advantages.
-
EYLEA HD and DUPIXENT delivered strong Q4 growth, with new launches and label enhancements driving momentum. The pipeline is expanding into neurology and ophthalmology, while strategic alliances and M&A remain focused on early-stage opportunities. Biosimilar competition and key trial readouts are expected to shape the year.
-
Dupixent and EYLEA HD continue to drive strong growth, with new launches and label enhancements supporting market expansion. The pipeline is robust, featuring near-term catalysts in oncology, geographic atrophy, and obesity, while life cycle management and new formulations aim to sustain leadership.
-
Earnings growth is expected to accelerate over the next 2–3 years, driven by EYLEA HD, DUPIXENT, and oncology launches, with significant margin and cash flow benefits from the Sanofi balance payoff. The pipeline is robust, with major advances in C5, obesity, and Factor XI, while the Regeneron Genetics Center provides a unique innovation edge.
-
The presentation highlighted a robust pipeline with 45 clinical candidates, strong commercial growth for Eylea HD and Dupixent, and a focus on internal R&D investment. Key late-stage programs in oncology, immunology, and rare diseases are expected to deliver pivotal data in 2024–2026.
Fiscal Year 2025
-
Fourth quarter 2025 revenue rose 3% year-over-year, led by strong growth in Dupixent, Libtayo, and EYLEA HD. The company anticipates multiple FDA approvals and significant pipeline progress in 2026, while continuing robust capital returns to shareholders.
-
Linvoseltamab, a BCMAxCD3 bispecific antibody, shows best-in-class efficacy and safety in late-line, early-line, and precursor multiple myeloma, with rapid, deep, durable responses and low toxicity. Multiple pivotal studies aim to simplify treatment and expand prevention, positioning it as a potential backbone therapy.
-
Announced major U.S. manufacturing investments and ongoing policy negotiations, with Eylea HD and Dupixent poised for growth through new indications and label enhancements. Oncology pipeline advances include promising data for Libtayo and Linvoseltamab, while obesity strategies focus on unique combination therapies.
-
Significant portfolio growth was highlighted, with Eylea HD, Dupixent, and Libtayo achieving new indications and strong uptake. The pipeline advanced across immunology, oncology, and rare diseases, while capital allocation and U.S. investment increased. Key 2026 objectives include optimizing brands and advancing late-stage assets.
-
Eylea HD continues to show strong volume growth, with label enhancements and prefilled syringe launches expected to further boost demand. Patient assistance funding remains a challenge, while capital deployment focuses on internal investment, M&A, and shareholder returns. Pipeline assets like Hanmi GLP-1 and Factor XI offer future growth opportunities.
-
Major melanoma and lung cancer trial readouts are expected in the next 18 months, with strong early data for LAG-3/PD-1 combinations. Commercial momentum continues in skin and lung cancers, and new pipeline assets and indications are advancing rapidly.
-
The Factor XI program features two antibodies designed for tailored anticoagulation, showing strong efficacy and safety in early studies. Genetic and clinical data support broad development across VTE, atrial fibrillation, and cancer-associated thrombosis, with pivotal data expected in 2027.
-
Q3 2025 saw strong growth in Dupixent, LIBTAYO, and EYLEA HD, offsetting EYLEA declines, with total revenues up 1% YoY and net income of $1.3B. Pipeline progress and U.S. manufacturing investments support long-term growth, while regulatory and pricing pressures remain key risks.
-
Strong commercial execution drove EYLEA HD growth, while DUPIXENT maintains momentum across indications. The pipeline is robust, with key oncology, complement, and obesity programs advancing, and capital allocation remains focused on R&D and shareholder returns.
-
The event highlighted a robust pipeline with more than 10 potential blockbusters, strong early data in oncology, immunology, and allergy, and a focus on internal R&D and selective early-stage deals. DUPIXENT maintains market leadership, and new allergy treatments show strong promise for both payer and consumer markets.
-
EYLEA HD and Dupixent continue to drive growth, with EYLEA HD label expansions delayed due to manufacturing issues but expected to accelerate adoption once resolved. The pipeline is advancing with promising data in myasthenia gravis, melanoma, and other areas, while the company maintains a long-term, innovation-driven business development strategy.
-
Strong Q2 financials and robust product growth were highlighted, with major pipeline advances in myasthenia gravis and PNH. Manufacturing investments aim to reduce supply risks, while Dupixent and Eylea HD continue to drive growth amid competitive pressures.
-
Q2 2025 saw strong growth in DUPIXENT, LIBTAYO, and EYLEA HD, offsetting EYLEA declines due to competition and affordability. Pipeline progress included new launches and regulatory milestones, while significant R&D and U.S. manufacturing investments continue. Guidance updated with lower expenses and no material tariff impact expected.
-
The meeting covered board elections, auditor ratification, and key governance proposals, with most items approved except for eliminating supermajority voting. Financial results showed strong growth in core products and significant R&D investment, while strategic plans focus on pipeline expansion and manufacturing capacity.
-
Focus remains on core brands and a robust pipeline, with key data readouts in oncology and neurology expected in the second half of the year. Manufacturing capacity is expanding, and new business development opportunities are being actively pursued.
-
The event highlighted a robust pipeline driven by advanced antibody and genetic technologies, with promising data in COPD, oncology, and anticoagulation. Strategic acquisitions and a unique genetics platform support ongoing innovation and leadership in key therapeutic areas.
-
First quarter saw challenges for EYLEA but strong growth for Dupixent and Libtayo. Regulatory and policy changes, including the new MFN order, are being closely monitored. Key pipeline readouts and product launches are expected in the second half of 2024.
-
Q1 2025 saw strong growth for Dupixent and Libtayo, but EYLEA U.S. sales declined sharply due to funding gaps and competition from Avastin. The pipeline advanced with multiple regulatory milestones, and significant investments were made in U.S. manufacturing and shareholder returns.
-
Eylea and Eylea HD remain market leaders with enhancements and pricing strategies to defend share. Major pipeline catalysts in 2024 include fianlimab, itepekimab, and new Dupixent indications, while oncology growth is driven by Libtayo and bispecifics.
-
Eylea HD is set for significant growth in 2025 with key FDA approvals and label expansions, while Dupixent continues to lead in multiple indications and prepares for new launches in COPD and CSU. Oncology and obesity pipelines are advancing, with several pivotal readouts and launches expected in 2024.
-
Four blockbuster drugs drive near-term growth, but the differentiated pipeline is the main value driver, with major advances in immuno-oncology, genetic medicines, and obesity. Multiple pivotal data readouts and regulatory milestones are expected in 2024.
Fiscal Year 2024
-
Q4 2024 saw 10% revenue growth, strong Dupixent, Libtayo, and Eylea HD performance, and the launch of a quarterly dividend and expanded share buybacks. Pipeline progress and label expansions are set to drive future growth amid ongoing competitive pressures.
-
Eylea franchise continues to perform strongly, with a focus on converting to Eylea HD amid competitive pressures and evolving market dynamics. Pipeline highlights include a new approach for geographic atrophy, promising COPD and oncology programs, and ongoing capital allocation toward R&D and share repurchases.
-
Eylea HD continues strong sales growth, with key milestones like prefilled syringe approval and label expansions expected in 2025. Dupixent's COPD launch is progressing well, with robust IP protection and new pipeline assets in development. Capital allocation favors R&D and share buybacks, while the obesity program anticipates pivotal data in 2025.
-
Q3 saw 11% revenue growth and 8% non-GAAP earnings growth, led by Dupixent, Eylea HD, and Libtayo. Dupixent revenues rose 24% and Eylea HD net sales grew 29% sequentially, with strong pipeline progress and continued R&D investment.
-
The oncology pipeline features strong clinical data for Libtayo, fianlimab, and bispecific antibodies, with Libtayo showing robust sales growth and new approvals for Ordspono in Europe. Linvoseltamab and costimulatory bispecifics demonstrate best-in-class potential, and the organization is positioned for further launches and data readouts.
-
EYLEA HD continues strong growth, with expanded market share and improved dosing durability. DUPIXENT maintains leadership in atopic dermatitis and prepares for a major COPD launch, while the pipeline advances in oncology, obesity, and allergies, with key data readouts expected in 2025.
-
Leadership is focused on transparency, capital allocation, and prudent investment, with a $3B share repurchase and potential dividend post-2026. EYLEA HD is gaining market share, Dupixent continues to expand indications, and key pipeline data and launches are expected in late 2024.
-
Q2 2024 saw 12% revenue growth to $3.55B, led by Eylea HD, Dupixent, and Libtayo. Dupixent grew 29% globally, Eylea HD maintained a 45% market share, and Libtayo sales rose 43%. FDA approval for linvoseltamab is delayed due to third-party manufacturing, but no safety issues were found.
-
The meeting approved all board nominees, auditor ratification, executive compensation, and a shareholder proposal for simple majority voting. Strong financial results were reported, with significant R&D investment and pipeline progress in ophthalmology, immunology, oncology, and obesity.
-
Capital allocation remains focused on R&D, manufacturing, and targeted M&A, with a new $3B share buyback and $17.5B in cash. EYLEA HD and Dupixent show strong momentum, while the pipeline advances in obesity, oncology, and allergy. Legal actions continue to protect key IP.
-
Key oncology programs show durable responses in melanoma and promising early data in NSCLC, with first-line and adjuvant settings prioritized. Systemic C5 inhibition and Factor XI antibodies advance in hematology, with pivotal readouts expected by year-end.